Smith Christopher K, Seddighi Reza, Cox Sherry K, Sun Xiaocun, Knych Heather K, Doherty Thomas J
Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN, USA.
Department of Large Animal Clinical Sciences, University of Tennessee, Knoxville, TN, USA.
Vet Anaesth Analg. 2017 Nov;44(6):1287-1295. doi: 10.1016/j.vaa.2017.07.004. Epub 2017 Aug 3.
To determine the effect of dexmedetomidine on induction dose and minimum infusion rate of propofol preventing movement (MIR).
Randomized crossover, unmasked, experimental design.
Three male and three female healthy Beagle dogs weighing 10.2 ± 2.8 kg.
Dogs were studied on three occasions at weekly intervals. Premedications were 0.9% saline (treatment P) or dexmedetomidine (1 μg kg, treatment PLD; 2 μg kg, treatment PHD) intravenously. Anesthesia was induced with propofol (2 mg kg and then 1 mg kg every 15 seconds) until intubation. Anesthesia was maintained for 90 minutes in P with propofol (0.5 mg kg minute) and saline, in PLD with propofol (0.35 mg kg minute) and dexmedetomidine (1 μg kg hour), and in PHD with propofol (0.3 mg kg minute) and dexmedetomidine (2 μg kg hour). The stimulus (50 V, 50 Hz, 10 ms) was applied to the antebrachium, and propofol infusion was increased or decreased by 0.025 mg kg minute based on a positive or negative response, respectively. Data were analyzed using a mixed-model anova and presented as mean ± standard error.
Propofol induction doses were 8.68 ± 0.57 (P), 6.13 ± 0.67 (PLD) and 4.78 ± 0.39 (PHD) mg kg and differed among treatments (p < 0.05). Propofol MIR values were 0.68 ± 0.13, 0.49 ± 0.16 and 0.26 ± 0.05 mg kg minute for P, PLD and PHD, respectively. Propofol MIR decreased 59% in PHD (p < 0.05). Plasma propofol concentrations were 14.04 ± 2.30 (P), 11.30 ± 4.30 (PLD) and 7.96 ± 0.72 (PHD) μg mL and dexmedetomidine concentrations were 0.68 ± 0.12 (PLD) and 0.89 ± 0.08 (PHD) ng mL at MIR determination.
Dexmedetomidine (1 and 2 μg kg) decreased propofol induction dose. Dexmedetomidine (2 μg kg hour) resulted in a significant decrease in propofol MIR.
确定右美托咪定对丙泊酚诱导剂量及预防体动的最小输注速率（MIR）的影响。
随机交叉、非盲法实验设计。
6只健康比格犬，3雄3雌，体重10.2±2.8千克。
犬只每周接受3次研究。预处理药物为静脉注射0.9%生理盐水（P组）或右美托咪定（1μg/kg，PLD组；2μg/kg，PHD组）。用丙泊酚（2mg/kg，随后每15秒1mg/kg）诱导麻醉直至插管。P组用丙泊酚（0.5mg·kg⁻¹·分钟⁻¹）和生理盐水维持麻醉90分钟，PLD组用丙泊酚（0.35mg·kg⁻¹·分钟⁻¹）和右美托咪定（1μg·kg⁻¹·小时⁻¹）维持麻醉，PHD组用丙泊酚（0.3mg·kg⁻¹·分钟⁻¹）和右美托咪定（2μg·kg⁻¹·小时⁻¹）维持麻醉。将刺激（50V，50Hz，10ms）施加于前臂，根据反应阳性或阴性分别将丙泊酚输注速率增加或降低0.025mg·kg⁻¹·分钟⁻¹。采用混合模型方差分析对数据进行分析，并以均值±标准误表示。
丙泊酚诱导剂量分别为8.68±0.57（P组）、6.13±0.67（PLD组）和4.78±0.39（PHD组）mg/kg，各治疗组间差异有统计学意义（p<0.05）。P组、PLD组和PHD组丙泊酚MIR值分别为0.68±0.13、0.49±0.16和0.26±0.05mg·kg⁻¹·分钟⁻¹。PHD组丙泊酚MIR降低了59%（p<0.05）。在测定MIR时，血浆丙泊酚浓度分别为14.04±2.30（P组）、11.30±4.30（PLD组）和7.96±0.72（PHD组）μg/mL，右美托咪定浓度分别为0.68±0.12（PLD组）和0.89±0.08（PHD组）ng/mL。
右美托咪定（1和2μg/kg）降低了丙泊酚诱导剂量。右美托咪定（2μg·kg⁻¹·小时⁻¹）使丙泊酚MIR显著降低。
